The feasibility and efficacy of high-dose melphalan followed by autologous hematopoietic stem cell transplantation in newly diagnosed elderly patients with multiple myeloma was analyzed prospectively. Fifty-six multiple myeloma patients, aged 65 or older, from 6 French centers were studied. The induction therapy was bortezomib-based in combination with dexamethasone and either thalidomide, cyclophosphamide or lenalidomide, for 4 to 6 cycles. 
Introduction
Two thirds of multiple myeloma (MM) patients are over 65 years of age at the time of diagnosis. As the general population becomes older, this proportion will increase in the future.
Autologous stem cell transplantation (ASCT) is a standard form of treatment for myeloma patients younger than 65 years (1) but is a controversial procedure above this age, mostly because of a suspected increased toxicity (2) (3) (4) (5) .
In elderly patients, only two randomized studies have compared a transplant versus no melphalan (HDT) plus ASCT for patients aged between 65 and 70 (6) . In contrast, the IFM 99-06 did not show any benefit of transplantation after melphalan (100 mg/m 2 ) as compared to a combination of melphalan, prednisone and thalidomide (7) . However, many subsequent studies, mostly retrospective or registry-based and performed before the latest drugs became available, have shown encouraging results with ASCT in patients over 65 (8) (9) (10) (11) (12) (13) . Some investigators even reported a successful outcome for patients above the age of 70 (14) (15) (16) (17) . A recent EBMT study showed that over the past few years, ASCT was performed more often, especially in the elderly population, and with a better outcome (18) .
The toxicity has considerably decreased due to better patient selection and improved supportive care. Geriatric assessment is nowadays routinely performed in the clinic, which helps the treatment decision (19, 20) .
Furthermore, new drugs have emerged such as the immunomodulatory drugs lenalidomide and pomalidomide and proteasome inhibitors like carfilzomib and ixazomib (21). These, used as single agents or more often in combination, together with the previous standard treatment, are rekindling the interest in ASCT for elderly patients (22).
We therefore initiated a multicenter prospective observational study, from 2013 to 2015 in 6
French centers, which included 56 myeloma patients aged 65 years or older, 50 of whom underwent ASCT after bortezomib-based induction.
Patients
Patients were eligible if they were more than 65 years of age and presented with symptomatic, measurable, newly diagnosed multiple myeloma. Between September 2012 and September 2014, a total of 56 newly diagnosed elderly MM patients were treated in 6 institutions in France. The diagnosis, clinical staging and prognostic score of MM were based on the Durie and Salmon staging system and the International Staging System (ISS) (23, 24). Seattle's hematopoietic cell transplantation specific comorbidity index (HCT-CI) was used to score the comorbidities (25). Baseline demographics, clinical and laboratory data at diagnosis and information on treatment and response were prospectively collected and recorded in the EBMT Promise (Med B) database. The patients gave informed consent. This prospective observational study was approved by the Ethics Committee/Institutional Review Board of Paris Île de France V and registered at www.ClinicalTrials.gov under the identifier NCT01671826.
Treatment
The primary objective was to assess the outcome of the patients and especially any toxicity of the treatment. Therapy was determined in each case by the physician responsible for the patient. The short term use of dexamethasone for emergent disease control was not considered as being conventional chemotherapy. ASCT was performed as upfront therapy after induction, provided the disease was not progressive.
Induction regimen
The induction regimen was bortezomib-based, either bortezomib plus dexamethasone (VD), bortezomib plus thalidomide plus dexamethasone (VTD), bortezomib plus cyclophosphamide plus dexamethasone (VCD), bortezomib plus lenalidomide plus dexamethasone (VRD), or melphalan plus prednisone plus bortezomib (MPV). The patients received four to six 21-day cycles according to the center's local guidelines.
Stem cell mobilization and collection
Peripheral blood hematopoietic stem cells were mobilized using the procedure in routine practice at each center. The cells were collected either after administration of high dose cyclophosphamide plus G-CSF or in the steady state after administration of G-CSF alone, plus plerixafor if needed.
Conditioning regimen and supportive care
To be eligible for transplantation, the patient had to have adequate organ function and no uncontrolled infection. The conditioning regimen consisted of melphalan (140 or 200 mg/m 2 ), given over one or two days, according to the physician's choice. Tandem ASCT was allowed and supportive care was given according to the current protocol in each institution.
Consolidation/maintenance
A short two-month consolidation phase three months post ASCT was allowed (lenalidomidedexamethasone, VD, VTD, VCD or VRD). No maintenance treatment was given.
Engraftment and disease response
The date of neutrophil engraftment was defined as the first of 3 consecutive days when the absolute neutrophil count in blood exceeded 0. 
Assessment of transplant-related toxicity
The transplant-related mortality (TRM) was defined as the percentage of patients dying, without relapse or progression, within a given time interval following transplantation.
Non-hematological toxicity was assessed by the local physician. The variables analyzed included bacterial and viral infections, gastro-enteric, renal (serum creatinine) and hepatic (bilirubin, alanine transaminase and aspartate transaminase) function and cardiotoxicity.
Statistics
The patients' demographic and clinical characteristics were summarized using the median and range for continuous variables and counts and percentages for categorical variables.
Progression-free survival (PFS) was defined as the time from the date of starting treatment to the date of disease progression or death from any cause. Overall survival (OS) was defined as the time from the date of starting treatment to death from any cause. PFS and OS curves were calculated using the Kaplan-Meier method.
We examined the relationship between outcomes and potential prognostic factors. The differences between the curves were evaluated using the log-rank test. Variables included the baseline patient factors, prognostic factors and treatment-related factors. The selection rule for multivariate analysis was a threshold of 20%. A multivariate Cox proportional hazards model was used to determine the independent predictors associated with extended OS.
Statistical testing was performed with a two-sided α = 0.05 and a 95% confidence interval.
Data were analyzed using R software, Version 2.15.1, and IBM SPSS statistics, Version 22.
Results

Patient characteristics
The patient demographics and disease characteristics are summarized in Table 1 . At the time of diagnosis, the median age was 67 years (range, 64-74) with 23% of patients being >70
years. There were 30 males and 26 females. The myeloma immunoglobulin subtypes were IgG (n=29), IgA (n=15), light chain (n=10) and other (n=2). The Salmon and Durie stage was III in 89% of cases (n=47) and the ISS scores were I (n=18, 35%), II (n=19, 37%) and III (n=14, 27%). High risk cytogenetic features (t (4;14) and/or del17p) were found in 9 cases (16%). Although 10% of patients had a serum creatinine level of >176 micromol/L, none underwent hemodialysis. Twenty-eight patients (53 %) received VTD, 9 (17 %) VCD, 9 (17 %) VD, 4 (7 %) MPV and 3 (6 %) VRD, with 11 patients (21%) requiring two lines of induction and one three lines.
At transplantation, the HCT-CI comorbidity scores were 0 (n=34), 1 (n=6), 2 (n=2), 3 (n=6), 6
(n=1) and unknown (n=1). The median age at the time of ASCT was 68 years and the median time from diagnosis to ASCT was 5 months. The median follow-up was 21 months (range, 6-31).
Mobilization
A median of 5.31 x 10 6 /kg CD34+ cells were collected. Thirty-two patients (57%) were mobilized with cyclophosphamide + G-CSF, 13 (23%) with G-CSF alone, 6 (10%) with G-CSF + plerixafor and one with cyclophosphamide + G-CSF + plerixafor. The number of mobilization courses was 1 (n=39), 2 (n=10) and unknown (n=2) and there were two failed mobilizations. There was no ex vivo manipulation of the autologous graft. The median number of CD34+ cells infused was 4.1 x 10 6 /kg (range, 1.7-7.6 x 10 6 /kg).
Patients unable to proceed to ASCT
In an intention to treat analysis, 6 of the 56 patients could not proceed to ASCT due to an early infectious death (n=1), serious comorbidity (n=2), disease refractoriness to the induction regimen (n=1), or failure to collect an adequate PBSC graft (n=2).
Engraftment
The conditioning regimen consisted of 140 mg/m² melphalan in 18 patients (36%) and 200 mg/m 2 melphalan in 32 (64%). Five patients received bortezomib in combination with melphalan (melphalan 200 mg/m 2 ), while 3 patients (6%) underwent tandem ASCT. The median time to neutrophil and platelet engraftment was 12 days (range, 9-56).There was no significant difference in the time to neutrophil or platelet engraftment between the two doses of melphalan.
Consolidation
Consolidation treatment, 3 months post ASCT, was given in 38 patients (68%). Thirteen (34%) received VTD, 6 (16%) VRD, 6 (16%) VCD, 5 (13%) VD, 4 (10%) RD, 2 (5%) lenalidomide, 1 (3%) MPV and 1 pomalidomide (3%). In 12 cases, the physician decided to administer no consolidation therapy.
Treatment-related toxicity
The day-100 post ASCT treatment-related mortality (TRM) was 0%. There was no significant difference in TRM between the two doses of melphalan. Table 2 summarizes the non-hematological toxicities appearing after ASCT. Infection within the first 100 days post ASCT occurred in 18 patients (36%) and non-infectious complications in 24 (48%). Gastrointestinal toxicities were frequent, the most common being oral mucositis (n=18, 36%) and diarrhea (n=3, 6%). Pulmonary infection occurred in 7 patients (14%).
Malnutrition was noted in 5 patients and thrombosis in 2, while one had a hemorrhage and another a cardiac complication. The incidence of infectious complications post ASCT and the response rate were comparable between the two doses of melphalan (p=0.28).
Response and survival
The disease status at the time of ASCT was defined as: complete response (CR) (n=12, 24%), very good partial response (VGPR) (n=19, 38%), partial response (PR) (n=17, 34%), or stable disease (SD)/non-responsive (n=2, 4%). The overall response rate on day 100 was 96% (CR: 34%, VGPR: 47%, PR: 15% and SD/non-responsive: 4%). At 3 months post ASCT, 68% of the patients were able to receive the planned consolidation treatment.The best responses were:
CR (n=20, 40%), VGPR (n=18, 36%), PR (n=9, 18%), progression (n=1, 2%) and unknown 
Univariate analysis
We performed a univariate analysis to identify the predictors independently associated with PFS and OS using the Cox proportional hazards model. The variables included in the analysis were the baseline patient characteristics (age, gender and type of myeloma protein), prognostic factors (albumin, β 2 microglobulin and ISS stage), disease status and melphalan dose at transplantation. We found the dose of the conditioning regimen to be the only significant prognostic factor for both PFS and OS. The ISS stage was prognostic for OS only (Table 3) .
Discussion
Over the past decade, the use of HDT followed by ASCT in combination with new drugs has substantially improved the outcome of younger patients with MM. However, the safety and efficacy of HDT in patients older than 65 years remain uncertain.
In this prospective study, the relatively low toxicity of the ASCT procedure for this patient population is very encouraging, with 0% TRM at 100 days post transplantation. In comparison, patients younger than 65 years have a 100-day TRM of around 1%. This is particularly striking considering that 10% of the patients had renal impairment at diagnosis with serum creatinine levels of >176 micromol/L, while 16% had high risk cytogenetic . Post ASCT maintenance is, however, still a controversial issue in young patients and more data will be needed before it can be implemented in an older patient population. Our results should also be compared to those of non-transplant approaches and in particular to the data obtained using new drugs. In the past, for patients aged 65 to 75 years, a combination of melphalan plus prednisone and thalidomide yielded a median PFS of 27.5 months and a median OS of 51.6 months, which was superior to the PFS of 19.4 months achieved using . In our study, the estimated PFS and OS rates at 2 years were 76% and 88%, respectively, which is encouraging. Moreover, these data are almost superimposable on those of Palumbo et al. using PAD induction followed by ASCT with lenalidomide consolidation and maintenance: after a median follow-up of 21 months, their 2-year PFS and OS rates were 69% and 86%, respectively (29). In the younger myeloma patients (<65 years), the combination of bortezomib and lenalidomide and dexamethasone as induction and consolidation post ASCT along with a one year lenalidomide maintenance gave even better results: with a median follow-up of 39 months, estimated 3-year progression-free and overall survival were 77% and 100%, respectively (32). Nevertheless, cross trial comparisons should be viewed with caution on account of the patient selection bias. This implies that selected elderly patients could benefit from auto-SCT, which might be superior to chemotherapy or new drug combinations.
Although we looked for prognostic factors, the only two significant factors detected in our univariate analysis of OS were the dose of the conditioning regimen and the ISS stage. This could be related to the small number of patients and the relatively short follow-up. However, the β 2 microglobulin level before transplantation, which is a confirmed prognostic variable in many studies, may lack significance in this elderly population (14) . β 2 microglobulin levels are higher in the elderly. This probably reflects an age-related decrease in creatinine clearance, rather than a high tumor burden.
The weaknesses of our study lie in the non-randomized nature of the trial and the highly selected patient population included, as reflected by the low Sorror score in most of our patients. Therefore, one may not be able to extrapolate ASCT to all newly diagnosed elderly myeloma patients. We also acknowledge that the induction, conditioning and consolidation regimens were very heterogeneous, which makes it more difficult to draw conclusions. The follow-up was also relatively short.
Other groups are currently studying the feasibility and efficacy of high dose melphalan in elderly patients, such as the DSMM group in Germany and the Freiburg team (13) .
Specifically, the latter has proposed a revised Myeloma Comorbidity Index for future frailty measurements which could help to define those patients fit enough to undergo stem cell transplantation (33).
In conclusion, these prospective multicenter results indicate that ASCT is a safe and effective mode of treatment for elderly and fit MM patients in the present era of novel induction agents.
One may note that patients above the age 70 did not have a worse prognosis. Thus, age per se should not be used as an exclusion criterion for ASCT. These results set the frame for a randomized comparison with non-transplant approaches in this patient subgroup. 
